Literature DB >> 12112393

Human immunodeficiency virus genotype and hypertriglyceridemia.

Soni J Anderson1, John F Bradley, Andrea Ferreira-Gonzalez, Carleton T Garrett.   

Abstract

Many HIV patients develop a progressive syndrome of abnormal body fat distribution accompanied by hypertriglyceridemia. Antiretroviral agents are thought to be etiologic in the syndrome, often termed "highly active antiretroviral therapy (HAART)-associated lipodystrophy." In the course of clinical HIV genotype testing, we observed that our HIV patients with hypertriglyceridemia had viral genotypes that were more highly mutated than those of our therapy-matched control patients. Hypertriglyceridemia was statistically associated with predicted resistance for three nucleoside reverse transcriptase inhibitors: zidovudine, abacavir, and stavudine. Statistical analysis of 51 patients in retrospect revealed a strong association of mutations at reverse transcriptase codons M41 and T215 with hypertriglyceridemia (chi-square (chi(2)) = 8.375, P=.0038; and chi(2)=7.445, P=.0064, respectively). This was in contrast to silent mutations, which occurred at equivalent rates in retroviral genotypes of patients with and without hypertriglyceridemia. The findings imply that the HIV genotype itself may be a significant etiologic factor in antiretroviral-associated lipodystrophy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12112393      PMCID: PMC6808024          DOI: 10.1002/jcla.10042

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  Atherogen lipid profile in HIV-1-infected patients with lipodystrophy syndrome.

Authors: 
Journal:  Eur J Intern Med       Date:  2000-10       Impact factor: 4.487

2.  Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

Authors:  A J Hance; V Lemiale; J Izopet; D Lecossier; V Joly; P Massip; F Mammano; D Descamps; F Brun-Vézinet; F Clavel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy.

Authors:  M Duong; J M Petit; L Piroth; M Grappin; M Buisson; P Chavanet; P Hillon; H Portier
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

4.  Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response.

Authors:  F Boufassa; A Dulioust; A S Lascaux; L Meyer; F Boué; J F Delfraissy; A Sobel; C Goujard
Journal:  HIV Clin Trials       Date:  2001 Jul-Aug

5.  Sex differences in HAART-associated dyslipidaemia.

Authors:  H Pernerstorfer-Schoen; B Jilma; A Perschler; S Wichlas; K Schindler; A Schindl; A Rieger; O F Wagner; P Quehenberger
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

Review 6.  Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.

Authors:  Jeanine Raulin
Journal:  Prog Lipid Res       Date:  2002-01       Impact factor: 16.195

7.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

Authors:  J Q Purnell; A Zambon; R H Knopp; D J Pizzuti; R Achari; J M Leonard; C Locke; J D Brunzell
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

Review 8.  Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.

Authors:  R Manfredi; F Chiodo
Journal:  J Infect       Date:  2001-04       Impact factor: 6.072

9.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

10.  Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex.

Authors:  D Mildvan; S G Machado; I Wilets; S E Grossberg
Journal:  Lancet       Date:  1992-02-22       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.